FDA approves GSK’s shingles vaccine

FDA approved Shingrix herpes zoster vaccine (HZ/su, GSK1437173A) from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to prevent shingles in adults ages 50 and older. The CDC's Advisory Committee on Immunization Practices (ACIP) will meet on Oct. 25 to discuss an analysis of the vaccine's cost effectiveness and vote on recommendations for its use. GSK said Shingrix will be available "shortly" pending ACIP's recommendation.

Last month, an FDA advisory committee unanimously recommended Shingrix's approval (see BioCentury Extra, Sept. 13)...